Search

Aprocitentan

Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]

Belumosudil

[A236634] It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC₅₀ 100 nM vs. 3 μM, respectively … [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925]

Pirbuterol

in a concentration between 10-50%. … While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing

Levallorphan

(From Martindale, The Extra Pharmacopoeia, 30th ed, p683) … An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties.

Aripiprazole lauroxil

The patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly. … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289].

N-acetyltyrosine

It is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated.

Tosedostat

Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. … It entered the clinical trial in patients with haematological malignancies.

Glyceryl stearate SE

Benzhydrocodone

[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]

Acrivastine

As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension